PetVivo Holdings, Inc. will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City. The company's participation highlights growing investor interest in veterinary biomedical innovations that address significant animal health challenges.
Chief Executive Officer John Lai will provide an overview of PetVivo's flagship products, including SPRYNG with OsteoCushion Technology and PrecisePRP. SPRYNG with OsteoCushion Technology represents an important advancement in veterinary joint care as an intra-articular injectable medical device consisting of sterilized, extra-cellular matrix microparticles. These microparticles have been found to adsorb onto the joint synovial lining of animals and integrate with subsynovial tissue, promoting restoration of proper joint mechanics and aiding in management of noninfectious joint pain sources such as joint instability, degenerative joint disease and osteoarthritis.
PrecisePRP marks a significant development in veterinary medicine as a first-in-class off-the-shelf platelet-rich plasma product designed for veterinarian use. Unlike conventional PRP mechanical kits requiring blood draws and centrifugation, PrecisePRP offers a leucoreduced, allogeneic, pooled, freeze-dried PRP that provides species-specific concentrated platelets for intra-articular administration in dogs and horses. The product guarantees uniformity and consistency with each vial containing 4 billion platelets at a concentration of 500,000 platelets per microliter and leucoreduced with less than 1500 white blood cells per microliter.
John D. Lowry, Founder and Chief Executive Officer of Spartan Capital Securities, LLC, emphasized the conference's mission to connect growth companies with appropriate investors and resources. The event, organized in partnership with B2i Digital, will showcase more than 60 carefully selected companies across technology, healthcare, consumer, mining, precious metals, and other high-growth sectors, with over 500 institutional and high-net-worth investors expected to attend.
David Shapiro, CEO of B2i Digital, noted that PetVivo's participation aligns with their commitment to connecting investors with diverse growth companies through digital marketing combined with face-to-face investor engagement. The conference will feature main-stage presentations, expert panels, curated one-on-one meetings, and extensive networking sessions designed to facilitate meaningful dialogue between growth companies and the investment community. For more information about the conference and registration details, please visit https://spartancapital.com.
The significance of PetVivo's presentation extends beyond investor relations, highlighting innovations that could transform veterinary care for companion animals and equines suffering from joint-related conditions. The company's products address a substantial market need for effective, convenient treatments for osteoarthritis and joint pain in animals, conditions that affect millions of pets worldwide and represent a growing segment within the veterinary healthcare industry. These developments demonstrate the increasing sophistication of veterinary medical devices and their potential to improve animal quality of life while creating new market opportunities in the expanding pet healthcare sector.
